{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:20:32Z","timestamp":1786112432667,"version":"build-2736575974"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n Cocaine and methamphetamine use disorders are major public health challenges with no approved pharmacological treatments. Reliance on complete abstinence as the sole end point in randomized controlled trials (RCTs) may hinder identification of effective therapies, as it is often overly stringent, whereas reduced stimulant use is a promising alternative given its association with improved health outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the treatment effect of pharmacological interventions tested in RCTs for stimulant use disorder, comparing reduced use to total abstinence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A meta-analysis was conducted of 12 US National Institute on Drug Abuse\u2013sponsored multisite RCTs conducted between 2001 and 2011 evaluating pharmacological interventions among people seeking treatment for cocaine or methamphetamine dependence. One-stage individual participant meta-analysis was used, and analyses were performed between August 2024 and November 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Tested pharmacotherapies included topiramate, bupropion, modafinil, ondansetron, tiagabine, cabergoline, reserpine, selegiline, and baclofen, each compared to placebo in double-blind trials. All participants received cognitive behavioral therapy regardless of treatment assignment.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was reduced drug use based on self-report, defined as a transition from high frequency (\u22655 days\/month) to low frequency (1-4 days\/month) of stimulant use or transition to abstinence. Abstinence, verified by urine toxicology, served as the secondary outcome. Mixed-effects logistic regression models with random study effects and inverse probability weighting were used to estimate pooled treatment effects.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 2000 participants were included (1134 in cocaine RCTs and 866 in methamphetamine RCTs), of whom 587 (29.4%) were women, with a mean (SD) age of 39.7 (8.6) years. Overall, 446 participants (31.2%, weighted) achieved reduced use, whereas 184 (13.3%, weighted) achieved abstinence at the trial end point. No significant differences were observed between the pooled active treatment and placebo groups for either outcome, overall or when stratified by stimulant type. In analyses of individual medications, cabergoline showed positive effect sizes (Cohen\n h<\/jats:italic>\n , 0.352; 95% CI, 0.115-0.590), indicating significantly higher rates of reduced cocaine use with cabergoline than pooled placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The present findings of this meta-analysis underscore the importance of evaluating a continuum of outcomes rather than focusing solely on abstinence in RCTs. The results suggest that reductions in stimulant use may serve as meaningful efficacy signals that could be underestimated when relying solely on stringent outcomes, such as abstinence.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.1092","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:30:35Z","timestamp":1780500635000},"page":"799","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder"],"prefix":"10.1001","volume":"83","author":[{"given":"Masoumeh","family":"Amin-Esmaeili","sequence":"first","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Mojtabai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Tulane Medical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland"},{"name":"Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island"},{"name":"Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Susukida","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"yoi260025r1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults.","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"yoi260025r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109001","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups - United States, 2004-2019.","volume":"227","author":"Kariisa","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yoi260025r3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mcna.2021.08.010","article-title":"Understanding stimulant use and use disorders in a new era.","volume":"106","author":"Ciccarone","year":"2022","journal-title":"Med Clin North Am"},{"key":"yoi260025r4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.drugalcdep.2017.08.036","article-title":"Health outcomes associated with crack-cocaine use: systematic review and meta-analyses.","volume":"180","author":"Butler","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"yoi260025r5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2105\/AJPH.2024.307948","article-title":"The fourth wave of the opioid epidemic: increasing combination of fentanyl with stimulants.","volume":"115","author":"Diekhans","year":"2025","journal-title":"Am J Public Health"},{"issue":"10","key":"yoi260025r8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: why it still matters, and the need for consilience.","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"yoi260025r9","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/jamapsychiatry.2025.2508","article-title":"Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: a review.","volume":"82","author":"Witkiewitz","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"yoi260025r10","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/acer.13897","article-title":"Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder.","volume":"42","author":"Witkiewitz","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"yoi260025r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107648","article-title":"Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder.","volume":"205","author":"Roos","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"yoi260025r12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/add.16409","article-title":"Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: findings from 13 multisite randomized clinical trials.","volume":"119","author":"Amin-Esmaeili","year":"2024","journal-title":"Addiction"},{"issue":"4","key":"yoi260025r13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.15288\/jsad.2019.80.431","article-title":"Patterns of cocaine use during treatment: associations with baseline characteristics and follow-up functioning.","volume":"80","author":"Roos","year":"2019","journal-title":"J Stud Alcohol Drugs"},{"key":"yoi260025r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108904","article-title":"Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.","volume":"226","author":"Amin-Esmaeili","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"yoi260025r16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/npp.2011.182","article-title":"The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders.","volume":"37","author":"Anton","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"yoi260025r18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials.","volume":"76","author":"Falk","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260025r19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/acer.13272","article-title":"Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels.","volume":"41","author":"Witkiewitz","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"yoi260025r20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1740774520972687","article-title":"Data management in substance use disorder treatment research: implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials.","volume":"18","author":"Susukida","year":"2021","journal-title":"Clin Trials"},{"issue":"5","key":"yoi260025r21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ.","volume":"36","author":"Burke","year":"2017","journal-title":"Stat Med"},{"issue":"15","key":"yoi260025r22","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/sim.8516","article-title":"Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: statistical recommendations for conduct and planning.","volume":"39","author":"Riley","year":"2020","journal-title":"Stat Med"},{"issue":"19","key":"yoi260025r23","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1002\/sim.8555","article-title":"One-stage individual participant data meta-analysis models for continuous and binary outcomes: comparison of treatment coding options and estimation methods.","volume":"39","author":"Riley","year":"2020","journal-title":"Stat Med"},{"issue":"1","key":"yoi260025r24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety and Depression Scale.","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"yoi260025r25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1360-0443.2011.03771.x","article-title":"Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.","volume":"107","author":"Elkashef","year":"2012","journal-title":"Addiction"},{"issue":"5","key":"yoi260025r26","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.npp.1301481","article-title":"Bupropion for the treatment of methamphetamine dependence.","volume":"33","author":"Elkashef","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"yoi260025r27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.drugalcdep.2015.01.036","article-title":"Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.","volume":"150","author":"Anderson","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"1-3","key":"yoi260025r28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","article-title":"Modafinil for the treatment of methamphetamine dependence.","volume":"120","author":"Anderson","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yoi260025r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145707007778","article-title":"A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.","volume":"11","author":"Johnson","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"yoi260025r30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.drugalcdep.2006.02.011","article-title":"A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.","volume":"84","author":"Johnson","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"1-2","key":"yoi260025r31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2009.04.015","article-title":"Modafinil for the treatment of cocaine dependence.","volume":"104","author":"Anderson","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"2-3","key":"yoi260025r32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.05.028","article-title":"A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence.","volume":"91","author":"Winhusen","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"2-3","key":"yoi260025r34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.drugalcdep.2007.05.021","article-title":"A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence.","volume":"91","author":"Winhusen","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"yoi260025r35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drugalcdep.2006.04.010","article-title":"Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.","volume":"85","author":"Elkashef","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"1-2","key":"yoi260025r36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2009.03.011","article-title":"Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals.","volume":"103","author":"Kahn","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"yoi260025r37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jclinepi.2012.12.017","article-title":"Individual participant data meta-analyses should not ignore clustering.","volume":"66","author":"Abo-Zaid","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"yoi260025r38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jrsm.1160","article-title":"Get real in individual participant data (IPD) meta-analysis: a review of the methodology.","volume":"6","author":"Debray","year":"2015","journal-title":"Res Synth Methods"},{"issue":"3","key":"yoi260025r39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/14656566.1.3.555","article-title":"Cabergoline.","volume":"1","author":"Colao","year":"2000","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"yoi260025r40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjp.2008.77","article-title":"Neuroplasticity in the mesolimbic dopamine system and cocaine addiction.","volume":"154","author":"Thomas","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"5","key":"yoi260025r41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003352.pub4","article-title":"Dopamine agonists for the treatment of cocaine dependence.","volume":"2015","author":"Minozzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"yoi260025r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1360-0443.2005.00988.x","article-title":"Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence.","volume":"100","author":"Leiderman","year":"2005","journal-title":"Addiction"},{"key":"yoi260025r43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1360-0443.2005.00991.x","article-title":"Randomized controlled pilot trial of cabergoline, hydergine and levodopa\/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).","volume":"100","author":"Shoptaw","year":"2005","journal-title":"Addiction"},{"issue":"1","key":"yoi260025r44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADT.0b013e31821e527d","article-title":"Long-term usefulness of cabergoline to patients in refraining from cocaine use after detoxification.","volume":"11","author":"Maremmani","year":"2012","journal-title":"Addict Disord Their Treat"},{"issue":"6","key":"yoi260025r45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000515398","article-title":"Cabergoline in treatment of methamphetamine-dependent patients and its effect on serum level of glial cell-derived neurotrophic factor: a randomized, double-blind, placebo-controlled clinical trial.","volume":"27","author":"Alipour","year":"2021","journal-title":"Eur Addict Res"},{"key":"yoi260025r46","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2025-1117","article-title":"Topiramate Therapy in Cocaine Use Disorder: A Systematic Review and meta-analysis of Randomized Controlled Trials.","author":"Shanmugam","year":"2025","journal-title":"Trends Psychiatry Psychother"},{"issue":"10","key":"yoi260025r47","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/add.16610","article-title":"Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder.","volume":"119","author":"Mojtabai","year":"2024","journal-title":"Addiction"},{"key":"yoi260025r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112841","article-title":"Cocaine craving and use during pharmacotherapy trials for cocaine use disorder: a multi-trajectory analysis.","volume":"275","author":"Mojtabai","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"yoi260025r49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JCP.0b013e3182983e73","article-title":"Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.","volume":"33","author":"Del Re","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"yoi260025r50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/ijerph9010192","article-title":"Do placebo response rates from cessation trials inform on strength of addictions?","volume":"9","author":"Moore","year":"2012","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"yoi260025r51","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.","volume":"37","author":"Litten","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"yoi260025r52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1740774509102560","article-title":"Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience.","volume":"6","author":"Rosa","year":"2009","journal-title":"Clin Trials"},{"issue":"3","key":"yoi260025r53","first-page":"343","article-title":"Strategies for dealing with missing data in clinical trials: from design to analysis.","volume":"86","author":"Dziura","year":"2013","journal-title":"Yale J Biol Med"},{"key":"yoi260025r15","volume-title":"Alcoholism: Developing Drugs for Treatment Guidance for Industry","author":"Food and Drug Administration","year":"2015"},{"key":"yoi260025r6","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS publication No. PEP24-07-021, NSDUH series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. July 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.pdf"},{"key":"yoi260025r7","unstructured":"Chan? B, Kondo? K, Ayers? C, . Pharmacotherapy for stimulant use disorders: a systematic review. US Department of Veterans Affairs; August 2018. https:\/\/pubmed.ncbi.nlm.nih.gov\/30715830\/"},{"key":"yoi260025r17","unstructured":"US Food and Drug Administration. FDA qualifies drug development tool to facilitate clinical trial research on alcohol use disorder. Accessed December 5, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-qualifies-drug-development-tool-facilitate-clinical-trial-research-alcohol-use-disorder"},{"key":"yoi260025r33","unstructured":"NIDA-CTO-0007: phase 2, double-blind, placebo-controlled trial of cabergoline for the treatment of cocaine dependence. US National Institute of Drug Abuse. Accessed December 5, 2025. https:\/\/datashare.nida.nih.gov\/study\/nida-cto-0007"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2849798\/jamapsychiatry_aminesmaeili_2026_oi_260025_1785440713.35754.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:00:48Z","timestamp":1785942048000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2849798"}},"subtitle":["A Meta-Analysis of 12 Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1092","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}